4 Maryland public school teachers receive top award for education in science, math
MARYLAND () — Four Maryland public school teachers have received the nation's highest award for their excellence in STEM education.
On Monday, Jan. 27, the Maryland State Department of Education announced that educators from Howard, Prince George's and Montgomery counties were among the most recent Presidential Award for Excellence in Mathematics and Science Teaching (PAEMST) recipients.
The award, established by Congress in 1983, is the highest recognition a kindergarten through 12th-grade science, technology, engineering or mathematics teacher can receive for 'outstanding teaching in the United States.'
As part of the honor, awardees receive a certificate signed by the president, a trip to Washington, D.C. to attend recognition events and professional development opportunities and a $10,000 award from the U.S. National Science Foundation.
Since 1983, the program has recognized over 5,500 teachers, according to the foundation. Up to 110 teachers are selected each year.
Tax season starts: Free tax services available in DC, Maryland, Virginia
This year, two science and two math teachers were selected from public schools in the state. The honorees include:
Prince George's County Public Schools:
Modupe Olafunmiloye– A Kenmoor Middle School science teacher, has also taught science and special education to students with cognitive disabilities at Buck Lodge Middle School for five years.
Montgomery County Public Schools:
Krishni Patrick– Has taught at Piney Branch Elementary School since 2007. A fifth-grade teacher, she has also taught third-grade and STEM. She began her career as a DC Teaching Fellow at Truesdell Elementary School, Leckie Elementary School and Thomson Elementary School. She then taught at Centreville Layton School in Delaware.
Joan Shane– Currently serves as the Mathematics Content Specialist (CS) at Sligo Middle School, where she has taught mathematics for the past 12 years. Shane spent the previous 11 years teaching fifth grade at Oakland Terrace Elementary School with a focus on mathematics.
Howard County Public Schools:
Kate Sandoval– Currently serves as an elementary mathematics specialist at Bollman Bridge Elementary School, where she previously taught fourth grade. Sandoval has worked in the Howard County Public School System for nine years, teaching at the elementary level.
In addition, two Maryland private school educators were also recognized.
To learn more about the program, click
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Onion
a day ago
- The Onion
Trump Escalates Musk Feud By Nuking Mars
WASHINGTON—After days of listening to the tech billionaire criticize his 'Big Beautiful Bill,' President Donald Trump escalated his feud with Elon Musk Friday by nuking Mars. 'Elon was 'wearing thin,' I asked him to leave, and then I blew up his stupid planet that no one else cared about,' Trump wrote in a post on Truth Social just moments after launching the entire U.S. stockpile of nuclear weapons in outer space. 'I don't mind Elon turning against me, but I should have blown up Mars months ago. This is one of the Greatest Bills ever presented to Congress. Good luck WITH YOUR COLONY NOW!' At press time, Musk tweeted that Trump only blew up Mars because the planet knew what the president had done with Jeffrey Epstein.
Yahoo
a day ago
- Yahoo
Physicists use AI to hunt for UAPs and UFOs
An international team of physicists has developed a new methodology to aid NASA and other government agencies in their ongoing investigations into unidentified aerial phenomena (UAPs). The result is a novel strategy integrating a specially designed artificial intelligence program that was partially inspired by the physicists' own hunt for elusive dark matter. More popularly known as unidentified flying objects or UFOs, UAPs aren't necessarily considered as outlandish as they were decades ago. Setting aside the various theories that point to mysterious visitors from another planet, analysis increasingly centers on determining more worldly explanations. UAPs are often explained by classified experimental aircraft, astronomical events, or simply a case of mistaken drone identity. Meanwhile, a small percentage of sightings continue to baffle experts. Over the last few years, the US government has attempted to present a more transparent approach to its UAP research, while the military continues a campaign to destigmatize reporting sightings among its ranks. In November 2024, Congress held a publicly televised joint subcommittee hearing about UAPs featuring a former US Navy rear admiral and NASA administrator. While not without its fair share of criticism, these and similar events are shifting the overarching narrative around unidentified aerial phenomenon. Researchers like Matthew Syzdagis at the University of Albany have followed this evolving discourse for years. An associate professor of physics focused on dark matter, Syzdagis recently began collaborating with over 30 colleagues around the world to determine if this approach to hunting dark matter could be adapted to the search for UAPs. Their results, published this month in the journal Progress in Aerospace Studies, offer a new interdisciplinary methodology to review the past and future UAP sightings. 'As this process moves forward, it's critical that future study of UAPs follows a rigorous, repeatable method that can be tested and confirmed by other researchers,' Syzdagis said in a statement. 'We aim to establish a roadmap for these efforts with this paper.' The team relied on an array of datasets and tools to build their framework, including publicly available Doppler weather information from the National Weather Service (NWS). The NWS data was used to corroborate observations from additional equipment and determine if any of them simultaneously recorded a given anomaly. They then utilized Cosmic Watch, a radiation-detection system, to assess if a target UAP observed by infrared cameras was accompanied by ionizing radiation. To help analyze the infrared data, Szydagis created a new software program called Custom Target Analysis Protocol (C-TAP) that utilizes machine learning alongside human verification to review individual camera frames on a pixel-by-pixel basis. Inspired by similar strategies used to scan for direct evidence of dark matter, C-TAP then flags and separates actual UAP observations from any digital noise. Finally, these results were overlaid with trigonometric calculations to exclude any known objects in the sky like satellites or the International Space Station. To test it all out, Szydagis and colleagues used their new methodology to review observable light and infrared images collected on a 2021 field expedition around Laguna Beach, California, amid a period of heightened UAP reports. In total, the team reviewed about one hour of triggered visible and night-vision video footage along with over 600 hours of infrared data and 55 hours of background radiation measurements. Of the multiple anomalies initially flagged, researchers were able to offer plausible and likely explanations for all sightings except for one—a collection of bright white dots inside a dark spot recorded across multiple videos. And even then, it seems unlikely that the UAP event was unique. 'At this point, none can be classified as true anomalies, although further study of remaining ambiguities may alter this conclusion,' the study's authors wrote in their conclusion. Moving forward, the team hopes their methodology will help more researchers around the world continue to vet UAP sightings on a scientific, unbiased basis. 'Given the longstanding, global nature of the UAP/UFO question, [and] the air safety and security implications of their presence… studying and understanding these phenomena is of great and urgent importance,' added University of Albany physics professor and study lead author Kevin Knuth.
Yahoo
2 days ago
- Yahoo
Novo Nordisk to present phase 3 trials across hemophilia portfolio, reinforcing commitment to research in rare blood disorders, at ISTH 2025
Key presentations include two updates from a phase 3 trial evaluating investigational treatment with Mim8 (denecimig) and five assessing treatment outcomes with concizumab in hemophilia A phase 3 trial analysis from FRONTIER5 will evaluate the safety of switching directly from emicizumab to Mim8 (denecimig) in people living with hemophilia A/B Findings from explorer7 and explorer8 phase 3 trials will assess data including non-joint bleeds, annualized bleeding rates and additional studies including thrombin generation with concizumab in hemophilia A/B PLAINSBORO, N.J., June 6, 2025 /PRNewswire/ -- Novo Nordisk today announced that new hemophilia data will be presented at the upcoming International Society on Thrombosis and Haemostasis (ISTH) Congress, June 21-25. Key data presentations across both hemophilia A and B (HA and HB), with and without inhibitors, will share insights on clotting, thrombin generation, bleeding episodes and medication impact, patient administration preferences, physician treatment satisfaction, and global real-world diagnosis and treatment data for joint bleeds. "At Novo Nordisk, we believe understanding the whole person and their journey is essential to addressing the unmet needs in people with hemophilia. Our research is rooted in a deep understanding of the hemophilia community, aiming to drive critical advancements across rare blood disorders in order to help address these unmet needs," said Stephanie Seremetis, Chief Medical Officer and CVP for Rare Disease at Novo Nordisk. "Through this latest research, we are honored to build on our long-standing legacy in rare blood disorders to support patients who face the challenges of this complex condition." New phase 3 data will be presented on Mim8, an investigational mimetic therapy designed to replicate the function of missing clotting factors.1 Analysis from the phase 3 FRONTIER5 trial will assess the safety and preferences of people with HA, with and without inhibitors, who switch from emicizumab to Mim8. In addition, new data from two prospective, multicenter, open label, phase 3 trials (explorer7 and explorer8) will investigate joint bleeds, non-joint bleeds, and annualized bleeding rate with preventive concizumab being investigated versus on-demand treatment across both HA and HB, with and without inhibitors. Summary of presentationsAccepted data at the 33rd ISTH Congress includes the following poster and oral presentations. Additional information can be found on the ISTH website. Full details of Novo Nordisk abstracts to be presented: Abstract title Abstract presentationdetails Hemophilia Investigational Mim8 FRONTIER5 direct switch study: Safety of initiating Mim8 prophylaxis without washout of emicizumab Oral presentation June 22 2:45-4:00 pm EST OC 20.4 Evaluating pen-injector handling and PROs in patients switching from emicizumab to Mim8 in FRONTIER5 Poster presentation June 23 1:45-2:45 pm EST PB0812 Mim8 enhances procoagulant activity of select hemophilia B-causing Factor IX variants (research collaboration) Oral presentation June 21 1:00-1:15 pm EST OC 03.1 Concizumab Non-joint bleeds in patients with hemophilia A or B with inhibitors: Concizumab explorer7 study Poster presentation June 23 1:45-2:45 pm EST PB0851 Annualized bleeding rates in hemophilia A/B and target joints: Concizumab explorer8 study Oral presentation June 24 2:45-4:00 pm EST OC 59.2 The effect of concizumab on thrombin generation in FVII deficient plasma Poster presentation June 24 1:45-2:45 pm EST PB1478 ISS study: TFPI slows prothombinase assembly when concizumab is bound to its second Kunitz domain Poster presentation June 24 1:45-2:45 pm EST PB1358 Taiwan study: Real-world efficacy of concizumab prophylaxis in a patient with hemophilia B and inhibitors Poster presentation June 23 1:45-2:45 pm EST PB0869 Pre-clinical data & general hemophilia In vitro activity of Inno8 in global hemostatic assays alone and with other hemostatic agents Oral presentation June 23 2:45-4:00 pm EST OC 39.5 Genomic integration of FVIII transgene in hepatocytes restores durable FVIII activity in vivo Oral presentation June 24 9:30-10:45 am EST OC 51.2 US physician-reported prophylactic treatment satisfaction and joint health of people with hemophilia Poster presentation June 24 1:45-2:45 pm EST PB1485 Joint bleed diagnosis and treatment delays in people with hemophilia: Global real-world data Poster presentation June 24 1:45-2:45 pm EST PB1423 About hemophiliaHemophilia is a rare inherited bleeding disorder that impairs the body's ability to make blood clots, a process needed to stop bleeding.2 It is estimated to affect approximately 1,125,000 people worldwide.3 There are different types of hemophilia, which are characterized by the type of clotting factor protein that is defective or missing. Hemophilia A is caused by a missing or defective clotting Factor VIII (FVIII), and hemophilia B is caused by a missing or defective clotting Factor IX (FIX).2 Hemophilia is often treated by replacing the missing clotting factor via intravenous infusions, also known as replacement therapy. However, sometimes the body can produce inhibitors as an immune response to the clotting factor replacement therapy. When this happens, the therapy may not work and can limit treatment options.5 About Novo NordiskNovo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With a U.S. presence spanning 40 years, Novo Nordisk U.S. is headquartered in New Jersey and employs over 10,000 people throughout the country across 12 manufacturing, R&D, and corporate locations in eight states plus Washington DC. For more information, visit Facebook, Instagram, and X. Contacts for further information Media:Liz Skrbkova (US)+1 609 917 0632USMediaRelations@ Ambre James-Brown (Global)+45 3079 9289Globalmedia@ Investors:Frederik Taylor Pitter (US)+1 609 613 0568fptr@ Jacob Martin Wiborg Rode (Global)+45 3075 5956jrde@ Sina Meyer (Global)+45 3079 6656 azey@ Ida Schaap Melvold (Global)+45 3077 5649 idmg@ Max Ung (Global)+45 3077 6414mxun@ References Østergaard H, Lund J, Greisen PJ, et al. A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice. Blood. 2021;138(14):1258-1268. MedlinePlus. Hemophilia. Accessed May 2025. Available at Iorio A, Stonebraker JS, Chambost H, et al.; Data and demographics committee of the World Federation of Hemophilia. Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries. Ann Intern Med. 2019;171(8):540–546. Centers for Disease Control and Prevention (CDC). Treatment of hemophilia. Accessed May 2025. Available at Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020;26 Suppl 6:1-158. Novo Nordisk is a registered trademark of Novo Nordisk A/S. © 2025 Novo Nordisk All rights reserved. US25NNG00026 June 2025 View original content to download multimedia: SOURCE Novo Nordisk Sign in to access your portfolio
